Vijay Kumar, the acting director of the Food and Drug Administration's Office of Therapeutic Products — the unit that reviews cell and gene therapies for safety and approval — is leaving his post, according to an internal email obtained by STAT. Kumar cited personal reflection and said the decision not to renew his detail was reached mutually with agency leadership. His exit extends an already unsettled period for the Center for Biologics Evaluation and Research, the FDA division that houses his office.
What the Office of Therapeutic Products Does
The Office of Therapeutic Products sits at the center of one of biotech's most consequential regulatory pipelines. It evaluates the clinical evidence behind cell therapies — treatments engineered from human cells — and gene therapies, which aim to correct or replace faulty genetic material. For drug developers, the office's leadership directly influences how applications are reviewed, what guidance gets issued, and how efficiently novel treatments move through the system. When that leadership rotates, developers and their investors pay attention, because regulatory continuity shapes timelines that can span years.
A Leadership Chain That Has Already Shifted Once
Kumar's departure is the latest turn in what STAT describes as a particularly rocky year of turnover inside CBER. He was elevated to the OTP director role by CBER Director Vinay Prasad after Prasad pushed out his predecessor, Nicole Verdun, a little over a year ago. Before taking the directorship, Kumar had served as a lead physician within the same office, making him an internal promotion rather than an outside appointment.
In his email, Kumar wrote that after careful reflection he had decided the time had come to move on, and noted that he and agency leadership had mutually agreed not to renew his detail.
Why Repeated Turnover Carries a Cost
The cell and gene therapy space runs on long development cycles and depends heavily on regulatory predictability. Each change at the top of the OTP resets institutional relationships, can shift how clinical data packages are interpreted, and introduces lag as a new director gets up to speed. Repeated turnover compounds that friction.
Prasad's tenure at CBER has already been defined by significant personnel churn, and Kumar's exit signals that the period of instability is not yet over. For companies with active gene therapy programs navigating the FDA pipeline, that means continued uncertainty about the regulatory environment — a variable that rarely moves a stock in a single session but steadily shapes how investors price clinical-stage risk.